
    
      1. Metastatic breast cancer patients should be definitively diagnosis based on
           histopathology, with ER-negative and PR-negative, FISH testing for her-2-negative

        2. All the patients enrolled will be given standard cyclophosphamide combined thiotepa and
           carboplatin chemotherapy and cellular therapy.Cellular therapy consisting of one cycle
           of chemotherapy followed by an apheresis and ex vivo cultures to generate DC and CIK,
           followed by low-dose Oral Cyclophosphamide .

        3. The response is assessed using Response Evaluation Criteria in Solid Tumor Group
           (RECIST) guidelines.

        4. Estimate time to progression, survival rates and clinical benefit response on patients.

        5. Find biomarkers associated with drug response.
    
  